Valneva SE

VALNEVA Declaration of shares and voting rights: August 31, 2025

03 Sep 2025 09:00:00 By Nasdaq GlobeNewswire

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate

02 Sep 2025 22:00:00 By Nasdaq GlobeNewswire

Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.

24 Aug 2025 22:00:00 By Nasdaq GlobeNewswire

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

17 Aug 2025 22:00:00 By Nasdaq GlobeNewswire

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

11 Aug 2025 22:00:00 By Nasdaq GlobeNewswire

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information

06 Aug 2025 22:17:50 By Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights: July 31, 2025

05 Aug 2025 09:00:00 By Nasdaq GlobeNewswire

Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly

11 Jul 2025 08:35:00 By Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights: June 30, 2025

03 Jul 2025 09:00:00 By Nasdaq GlobeNewswire

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus

25 Jun 2025 22:00:00 By Nasdaq GlobeNewswire

Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance

25 Jun 2025 08:45:00 By Nasdaq GlobeNewswire

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

05 Jun 2025 08:45:00 By Nasdaq GlobeNewswire

[Valneva SE] Declaration of shares and voting rights - May 2025

04 Jun 2025 22:30:00 By Nasdaq GlobeNewswire

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

03 Jun 2025 22:00:00 By Nasdaq GlobeNewswire

Valneva to Participate at U.S. and European Investor Conferences in June

26 May 2025 08:30:00 By Nasdaq GlobeNewswire

Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States

11 May 2025 22:00:00 By Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights: April 30, 2025

07 May 2025 09:00:00 By Nasdaq GlobeNewswire

Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly

07 May 2025 08:45:00 By Nasdaq GlobeNewswire

Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates

06 May 2025 22:00:13 By Nasdaq GlobeNewswire

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities

26 Apr 2025 10:10:00 By Nasdaq GlobeNewswire